Search results
Results from the WOW.Com Content Network
By the third or fourth month, erythropoiesis moves to the liver. [3] After seven months, erythropoiesis occurs in the bone marrow. Increased levels of physical activity can cause an increase in erythropoiesis. [4] However, in humans with certain diseases and in some animals, erythropoiesis also occurs outside the bone marrow, within the spleen ...
Megakaryocyte–erythroid progenitor cells must commit to becoming either platelet-producing megakaryocytes via megakaryopoiesis or erythrocyte-producing erythroblasts via erythropoiesis. [2] [3] Most of the blood cells produced in the bone marrow during hematopoiesis come from megakaryocyte–erythroid progenitor cells. [4]
[8] [9] Epoetin alfa is an erythropoiesis-stimulating agent. [8] It stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Epoetin alfa is developed by Amgen. [8] It is on the World Health Organization's List of Essential Medicines. [10]
Erythropoiesis-stimulating agents (ESA) are medications which stimulate the bone marrow to make red blood cells. [1] They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS. [1] [2] In these situations they decrease the need for blood transfusions. [2]
In the process of erythropoiesis (red blood cell formation), reticulocytes develop and mature in the bone marrow and then circulate for about a day in the blood stream before developing into mature red blood cells. Like mature red blood cells, in mammals, reticulocytes do not have a cell nucleus.
CFU-E is a stage of erythroid development between the BFU-E stage and the pro-erythroblast stage. CFU-E colony assay is designed to detect how many colony-forming-units of erythroid lineage there are in a hematopoietic tissue (bone marrow, spleen, or fetal liver), which may be reflective of the organism’s demand for oxygen delivery to the tissues or a hematopoietic disorder.
CFU-GEMM is a colony forming unit that generates myeloid cells.CFU-GEMM cells are the oligopotential progenitor cells [1] [2] for myeloid cells; they are thus also called common myeloid progenitor cells or myeloid stem cells.
Dyserythropoiesis refers to the defective development of red blood cells, also called erythrocytes. [1] This problem can be congenital, acquired, or inherited. [2] Some red blood cells may be destroyed within the bone marrow during the maturation process, whereas others can enter the circulation with abnormalities. [3]